Details
Daveris Indications
To reduce high intraocular pressure in patients with ocular hypertension or open-angle glaucoma.
To reduce high intraocular pressure in children aged 2 months to 18 years with ocular hypertension or childhood glaucoma.
Contradictions
Hypersensitivity to the active substance or to other components of the medicinal product.
Dosage & Administration
The drug is intended for topical use.
Adults (including elderly patients)
Instill 1 drop in the conjunctival sac (bags) of the affected eye (s) once a day. The optimal effect is achieved by administering the dose in the evening.
After instillation, it is recommended to clamp the nasolacrimal duct or slightly close the eyelids. This reduces the systemic absorption of drugs administered to the eye, which may reduce the likelihood of systemic side effects.
If more than one ophthalmic agent is used for topical use, the interval between their use should be at least 5 minutes (see section "Interaction with other medicinal products and other forms of interaction").
If a dose is missed, treatment should be continued from the next scheduled dose. The dose should not exceed 1 drop in the affected eye (s) once a day.
If another ophthalmic antiglaucoma agent is replaced by Daveris, the other drug should be discontinued and Daveris should be started the next day.
To prevent contamination of the dropper edge and the contents of the vial, be careful not to touch the eyelids, adjacent areas or other surfaces with the edge of the dropper vial.
Patients with impaired liver and kidney function
Travoprost has been studied in patients with hepatic impairment (mild to severe) and in patients with renal impairment (mild to severe) (creatinine clearance below 14 ml / min). There is no need to adjust the dose for such patients (see section "Pharmacological properties").
Patients who wear contact lenses
See section "Features of application".
Children.
The drug can be used in children aged 2 months to 18 years at the same dosage regimen as adults. However, data on the age group from 2 months to 3 years (9 patients) are limited (see section "Pharmacological properties").
The safety and efficacy of travoprost in children under 2 months of age have not been established. No data available.
